A yau, kiba ya zama annoba a duniya, kuma yawan kiba ya yi tashin gwauron zabi a kasashen duniya.A cewar Hukumar Lafiya ta Duniya, an kiyasta cewa kashi 13 cikin 100 na manya a duniya suna da kiba.Mafi mahimmanci, kiba na iya ƙara haifar da ciwo na rayuwa, wanda ke tattare da matsaloli daban-daban kamar nau'in ciwon sukari na 2, hauhawar jini, steatohepatitis marasa shan giya (NASH), cututtukan zuciya, da ciwon daji.
A cikin Yuni 2021, FDA ta amince da Semaglutide, maganin rage nauyi wanda Novo Nordisk ya haɓaka, azaman Wegovy.Godiya ga kyakkyawan sakamako na asarar nauyi, kyakkyawan bayanin martabar aminci da turawa daga mashahuran mashahuran kamar Musk, Semaglutide ya zama sananne sosai a duniya har ma yana da wuya a samu.Dangane da rahoton kudi na Novo Nordisk na 2022, Semaglutide ya samar da tallace-tallace har zuwa dala biliyan 12 a cikin 2022.
Kwanan nan, wani binciken da aka buga a cikin Jarida ya nuna cewa Semaglutide kuma yana da fa'idar da ba zato ba tsammani: maido da aikin kisa na halitta (NK) a cikin jiki, ciki har da ikon kashe kwayoyin cutar kansa, wanda ba ya dogara da sakamakon asarar nauyi na miyagun ƙwayoyi.Wannan binciken kuma labari ne mai kyau ga marasa lafiya masu kiba ta amfani da Semaglutide, yana ba da shawarar cewa miyagun ƙwayoyi yana da fa'idodi masu mahimmanci na rage haɗarin cutar kansa baya ga asarar nauyi.Wani sabon ƙarni na kwayoyi, wanda Semaglutide ke wakilta, yana jujjuya maganin kiba kuma ya ba masu bincike mamaki tare da tasirinsa mai ƙarfi.
Don haka, wa zai iya samun asarar nauyi mai kyau daga gare ta?
A karon farko, tawagar ta raba masu kiba zuwa rukuni hudu: wadanda suke bukatar karin abinci don jin koshi (yunwar kwakwalwa), masu cin abinci daidai gwargwado amma suna jin yunwa daga baya (yunwar hanji), masu cin abinci don shawo kan matsalar. motsin zuciyarmu (yunwar motsin rai), da waɗanda ke da ɗan jinkirin metabolism (jinkirin metabolists).Kungiyar ta gano cewa gut da ke fama da matsananciyar yunwar marasa lafiya sun amsa mafi kyau ga waɗannan sabbin magungunan asarar nauyi don dalilai da ba a san su ba, amma masu binciken sun yi hasashen cewa yana iya zama saboda matakan GLP-1 ba su da girma, wanda shine dalilin da ya sa suka sami nauyi kuma, sabili da haka, mafi kyawun nauyi. hasara tare da GLP-1 agonists mai karɓa.
Yanzu ana ɗaukar kiba a matsayin cuta na yau da kullun, don haka ana ba da shawarar waɗannan magunguna don dogon magani.Amma har yaushe ne hakan?Ba a bayyana ba, kuma wannan ita ce hanyar da za a bincika a gaba.
Bugu da ƙari, waɗannan sababbin magungunan rage nauyi sun kasance masu tasiri sosai cewa wasu masu bincike sun fara tattauna yawan nauyin da aka rasa.Rage kiba ba wai kawai yana rage kitse ba har ma yana haifar da asarar tsoka, kuma zubar da tsoka yana kara hadarin cututtukan zuciya da jijiyoyin jini, osteoporosis, da sauran yanayi, wanda ke da matukar damuwa ga tsofaffi da masu fama da cututtukan zuciya.Wadannan mutane suna fama da abin da ake kira lalatawar kiba - cewa asarar nauyi yana da alaƙa da mace-mace mafi girma.
Don haka, ƙungiyoyi da yawa sun fara bincika ƙananan tasirin amfani da waɗannan sabbin magungunan rage nauyi don magance matsalolin da ke da alaƙa da kiba, kamar su apnea, cututtukan hanta mai kitse, da nau'in ciwon sukari na 2, wanda ba lallai ba ne ya buƙaci asarar nauyi.
Lokacin aikawa: Oktoba-23-2023